[A23-56] Sacubitril/valsartan (heart failure, children and adolescents) – Benefit assessment according to §35a Social Code Book V
Last updated 07.12.2023
Project no.:
A23-56
Commission:
Commission awarded on 14.06.2023 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Heart and circulation
Children and adolescents aged 1 year or older with symptomatic chronic heart failure with left ventricular systolic dysfunction
Added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
The current version 1.1 of the dossier assessment replaces version 1.0 published on 2023-09-15.
https://dx.doi.org/10.60584/A23-56_V1.1
| Project no. | Title | Status |
|---|---|---|
| A15-60 | Sacubitril/valsartan - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A23-103 | Sacubitril/valsartan (heart failure, children and adolescents) – Addendum to Commission A23-56 | Commission completed |
Federal Joint Committee (G-BA)
2023-12-07 A G-BA decision was published.